查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602691

阿維莫泮市場：按治療應用、最終用戶分類 - 全球預測 2025-2030

Alvimopan Market by Therapeutic Application (Opioid-Induced Constipation, Postoperative Ileus Prevention), End-User (Hospitals, Surgical Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年阿爾維磨盤市值為62億美元，預計2024年將達65.1億美元，複合年成長率為5.23%，到2030年將達到88.7億美元。

阿維莫泮是一種周邊μ鴉片受體拮抗劑，主要用於透過減輕鴉片類藥物引起的胃腸道副作用來促進腸切除手術後胃腸道恢復。阿維莫泮的需求源於其在提高術後復健率、縮短住院時間和降低醫療費用方面的重要作用，特別是考慮到我正在關注的全球外科手術數量不斷增加。在醫療保健領域，它主要用作醫院和手術中心的術後治療。 Alvimopan 的最終用途範圍也擴展到製藥領域，重點是加強術後護理和病患管理通訊協定。醫療保健系統對微創手術和快速復健通訊協定的日益重視是該市場的關鍵成長要素。探索將適應症和範圍擴展到胃腸道恢復以外的藥物聯合治療存在潛在的商機。與醫療機構的策略夥伴關係可以提高您的市場滲透率和覆蓋範圍。然而，監管挑戰、高成本和嚴格的劑量通訊協定等限制構成了主要障礙。由於相關嚴格指導方針導致的潛在心血管風險和抗藥性也可能阻礙市場擴張。其目的是透過先進的藥物輸送系統（例如基於奈米顆粒的技術）來提高阿維莫泮的生物有效性和療效，並透過利用人工智慧主導的藥物設計策略來最佳化治療效果，存在創新機會。研究可以集中在開發更廣泛的μ鴉片受體拮抗劑，以保留阿維莫泮的益處，同時降低風險。阿維莫泮的市場是利基且高度專業化的，有強力的臨床證據支持其功效，但必須適應複雜的監管環境並證明其安全性才能維持成長。了解市場動態並根據您的需求整合行銷策略可以讓您在這個不斷發展的領域中獲得競爭優勢。

主要市場統計
基準年[2023] 62億美元
預測年份 [2024] 65.1億美元
預測年份 [2030] 88.7億美元
複合年成長率（%） 5.23%

市場動態：揭示快速發展的 Alvimopan 市場的關鍵市場洞察

Alvi Mopan 市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 手術介入的增加，包括腹部手術
    • 提高對鴉片類藥物引起的併發症的認知和管理策略
    • 改善世界各地的醫療保健設施
  • 市場限制因素
    • 法規嚴格、核准流程長
  • 市場機會
    • 探索阿維莫泮治療應用的研發計劃
    • 增加對公共和私人醫療基礎設施的投資
  • 市場挑戰
    • 阿維莫泮副作用的風險

波特的五力：駕馭阿維莫泮市場的策略工具

波特的五力框架是了解 Alvimopan 市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 Alvi Mopan 市場的外部影響

外部宏觀環境因素在塑造阿維莫泮市場表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解 Alvi Mopan 市場的競爭狀況

對 Alvimopan 市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 Alvimopan 市場供應商績效評估

FPNV定位矩陣是評估Alvimopan市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 Alvi Mopan 市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對阿維莫泮市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 手術介入的增加，包括腹部手術
      • 提高對鴉片類藥物引起的併發症的認知和管理策略
      • 改善世界各地的醫療保健設施
    • 抑制因素
      • 法規嚴格、核准流程長
    • 機會
      • 探索阿維莫泮治療應用的研發舉措
      • 增加對公共和私人醫療基礎設施的投資
    • 任務
      • 與阿維莫泮相關的副作用風險
  • 市場區隔分析
    • 治療應用：緩解鴉片類藥物引起的便秘的多種應用
    • 最終使用者：阿維莫泮在手術中心越來越受歡迎，用於治療術後腸阻塞
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 依治療用途分類的阿維莫泮市場

  • 鴉片類藥物引起的便秘
  • 術後腸阻塞的預防

第7章 Alvimopan 市場：依最終用戶分類

  • 醫院
  • 手術中心

第8章 南北美洲阿維莫泮市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 Alvi Mopan亞太區市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲阿維莫泮市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Hikma Pharmaceuticals 在美國推出促進腸胃恢復的 Alvimopan 膠囊
  • 戰略分析和建議

公司名單

  • Adolor Corporation
  • Adooq Bioscience LLC
  • Hikma Pharmaceuticals PLC
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-151228454438

The Alvimopan Market was valued at USD 6.20 billion in 2023, expected to reach USD 6.51 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 8.87 billion by 2030.

Alvimopan is a peripherally acting μ-opioid receptor antagonist primarily used to accelerate gastrointestinal recovery following bowel resection surgeries by mitigating opioid-induced gastrointestinal side effects. The necessity of Alvimopan stems from its critical role in enhancing postoperative recovery rates, reducing hospital stays, and decreasing healthcare costs, particularly in light of the increasing number of surgical procedures worldwide. It is predominantly applied in the healthcare setting by hospitals and surgical centers as a postoperative treatment agent. Alvimopan's end-use scope extends to the pharmaceutical sector with a focus on postoperative care and enhanced patient management protocols. The increasing emphasis on minimally invasive surgeries and rapid recovery protocols within healthcare systems is a significant growth factor for this market. Potential opportunities lie in expanding indications for its use beyond gastrointestinal recovery and exploring combination drug therapies that could widen its applicability. Engaging in strategic partnerships with healthcare institutions can enhance market penetration and reach. However, limitations such as regulatory challenges, high cost, and strict administration protocols pose significant hurdles. Resistance due to potential cardiovascular risks and associated stringent guidelines may also deter market expansion. Innovation opportunities exist in enhancing the bioavailability and efficacy of Alvimopan through advanced drug delivery systems, such as nanoparticle-based technologies or harnessing AI-driven drug design strategies to optimize its therapeutic efficacy. Research could focus on developing a broader spectrum μ-opioid receptor antagonist that retains the benefits of Alvimopan while reducing risks. The market for Alvimopan is niche and highly specialized, driven by strong clinical evidence supporting its effectiveness, but it requires navigating complex regulatory landscapes and demonstrating safety to sustain growth. Understanding market dynamics and integrating tailored marketing strategies can provide competitive advantages in this evolving domain.

KEY MARKET STATISTICS
Base Year [2023] USD 6.20 billion
Estimated Year [2024] USD 6.51 billion
Forecast Year [2030] USD 8.87 billion
CAGR (%) 5.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alvimopan Market

The Alvimopan Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in surgical interventions including abdominal surgeries
    • Growing awareness and management strategies for opioid-induced complications
    • Improved healthcare facilities worldwide
  • Market Restraints
    • Strict regulations and long approval processes
  • Market Opportunities
    • R&D initiatives for exploring therapeutic applications of alvimopan
    • Increasing investments in public and private healthcare infrastructure
  • Market Challenges
    • Risk of associated side effects of alvimopan

Porter's Five Forces: A Strategic Tool for Navigating the Alvimopan Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alvimopan Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alvimopan Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alvimopan Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alvimopan Market

A detailed market share analysis in the Alvimopan Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alvimopan Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alvimopan Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alvimopan Market

A strategic analysis of the Alvimopan Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alvimopan Market, highlighting leading vendors and their innovative profiles. These include Adolor Corporation, Adooq Bioscience LLC, Hikma Pharmaceuticals PLC, Manus Aktteva Biopharma LLP, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Alvimopan Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Application, market is studied across Opioid-Induced Constipation and Postoperative Ileus Prevention.
  • Based on End-User, market is studied across Hospitals and Surgical Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in surgical interventions including abdominal surgeries
      • 5.1.1.2. Growing awareness and management strategies for opioid-induced complications
      • 5.1.1.3. Improved healthcare facilities worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations and long approval processes
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D initiatives for exploring therapeutic applications of alvimopan
      • 5.1.3.2. Increasing investments in public and private healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of associated side effects of alvimopan
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation
    • 5.2.2. End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alvimopan Market, by Therapeutic Application

  • 6.1. Introduction
  • 6.2. Opioid-Induced Constipation
  • 6.3. Postoperative Ileus Prevention

7. Alvimopan Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Surgical Centers

8. Americas Alvimopan Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Alvimopan Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Alvimopan Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Hikma Pharmaceuticals Launches Alvimopan Capsules for Enhanced Gastrointestinal Recovery in the US
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adolor Corporation
  • 2. Adooq Bioscience LLC
  • 3. Hikma Pharmaceuticals PLC
  • 4. Manus Aktteva Biopharma LLP
  • 5. Merck & Co., Inc.
  • 6. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ALVIMOPAN MARKET RESEARCH PROCESS
  • FIGURE 2. ALVIMOPAN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALVIMOPAN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALVIMOPAN MARKET DYNAMICS
  • TABLE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023